0001708599-26-000022
SEC filingSerina Therapeutics, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 27, 2026. This amendment was filed solely to correct an incorrect version of the Auditor Consent (Exhibit 23.1) that was inadvertently included in the original filing dated March 25, 2026. The company states that, except for this correction and the inclusion of new officer certifications, it has not modified or updated any disclosures from the original report. The filing confirms the company's common stock (SER) is registered on the NYSE American. As of June 30, 2025, the aggregate market value of voting common stock held by non-affiliates was $21.8 million, and as of March 18, 2026, there were 12,314,159 shares of common stock outstanding. The document does not contain the primary financial statements, management discussion, or operational results for FY 2025, as this filing is a limited-scope amendment addressing a specific exhibit.
This document is Amendment No. 1 (Form 10-K/A) to Serina Therapeutics, Inc.'s Annual Report for the fiscal year ended December 31, 2025. The amendment was filed on March 27, 2026. Its sole purpose, as explicitly stated in the 'EXPLANATORY NOTE,' is to replace an incorrect version of the Auditor Consent (Exhibit 23.1) that was included in the original 10-K filed on March 25, 2026. The company emphasizes that no other disclosures from the original report have been modified or updated. Consequently, this filing does not contain the income statement, balance sheet, cash flow statement, or Management's Discussion and Analysis (MD&A) for FY 2025. The document provides administrative details, including the company's address, ticker symbol (SER), and filing statuses. It confirms the aggregate market value of voting common stock held by non-affiliates was $21.8 million as of June 30, 2025, and the number of outstanding shares of common stock was 12,314,159 as of March 18, 2026.
No revenue, segment, or product data is presented in this amendment. The filing's explanatory note clearly states its limited scope is to correct Exhibit 23.1 and provide new officer certifications. It does not incorporate or amend the financial performance sections (e.g., Part II, Item 7 - MD&A) where revenue drivers, segment breakdowns, or geographic mix would typically be discussed. Therefore, no analysis of revenue sources or growth drivers can be performed from the content provided.
No profitability metrics, margin data, or cost structure information is disclosed in this amendment. The document lacks the consolidated financial statements (income statement) necessary to calculate or discuss gross margin, operating income, net income, or related trends. The filing's purpose is administrative, not to present or update financial results.
No cash flow or balance sheet data is provided in this amendment. The filing does not include the statement of cash flows, balance sheet, or related notes. Key metrics such as operating cash flow, free cash flow, debt levels, or liquidity position are not disclosed. The only financial-related figures are the non-affiliate market value ($21.8 million as of June 30, 2025) and share count (12,314,159 as of March 18, 2026), which are administrative disclosures rather than performance metrics.
No forward-looking statements, management guidance, or discussion of strategic priorities are included in this amendment. The explanatory note explicitly states the amendment does not reflect events occurring after the date of the original 10-K filing and continues to speak only as of that date. Risk factors, which are typically found in Part I, Item 1A of a 10-K, are not amended or presented here. The filing is purely corrective for a specific exhibit and related certifications.